Compare Pfizer Inc (PFE) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Starbucks Corp — how do they compare? Pfizer Inc trades at $27.71 (market cap $158.56B), while Starbucks Corp trades at $93.2 (market cap $106.26B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Starbucks Corp for 190 Days on average.
| PFE | SBUX | |
|---|---|---|
Market Cap | $158.56B | $106.26B |
Volume | 44,138,282 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $108.55 |
52-Week Low | $23.67 | $78.46 |
Typical Hold Time | 158 Days | 190 Days |
Enterprise Value | $210.06B | $125.08B |
Dividend Yield | 6.18% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Starbucks (SBUX) trades at $93.58, down 2.63% amid bearish technical signals and recent store closure announcements. The company shows mixed fundamentals with a high P/E ratio of 54.09 but strong recent earnings beats. Revenue growth remains modest at $37.18B for 2025, while net income declined to $1.86B. Analyst consensus remains positive with a $115.50 price target despite ongoing restructuring challenges and geopolitical tensions in China operations.
The stock faces near-term pressure from operational restructuring but maintains long-term growth potential through international expansion and brand strength. Key risks include labor relations, Chinese market exposure, and execution of store optimization strategy. With 47% analyst buy ratings and solid dividend payments, SBUX offers value for patient investors despite current headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
